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Purpose: This investigation is intended to obtain differ-
entially expressed genes related to human malignant glioma
using Subtractive hybridization. Materials and Methods:
Subtractive hybridization is potentially faster methods for
identifying differentially expressed genes associated with a
particular disease state. We identified 7 over-expressed genes
which were not homologous to any of the known genes in the
Genbank
TM database. Results: Using semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR), the mRNA
expression levels of these 7 genes were higher in human
glioblastomas tissue than in non-tumor brain tissue. In order
to learn more about the expression profile of these genes,
RT-PCR was performed using various commercially available
human carcinoma cell lines. Some of these new genes were
over-expressed in human glioma cell line, but not the
expressed in other human cancer cell line. Conclusion: Theses
cloned new genes may play a role in brain tumorigenesis.
Further studies including verification of oncogene, cancer
protein, and glioblastoma induction in animal model are
needed.
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INTRODUCTION
The development of cancer is a complex and
multi-step process in which a series of progressive
changes culminate in deregulation of all pro-
liferation in nervous cells.
1 Alterations of gene
expression and several genetic aberrations have
been shown to occur during malignant growth,
transformation, and progression of glioblastoma.
1,2
The glioblastoma is the most common malignant
brain tumor in adults.
3 Their distinct ability to
invade the normal surrounding tissue makes them
difficult to completely remove surgically, thus
accounting for the extraordinarily high lethality
associated with malignant gliomas.
4 A variety of
genetic alterations in human gliomas comprise
signal transduction and cell cycle arrest control of
cellular processes.
Current methods for comparing gene-expression
profile changes in different tissues or different
pathological specimens include mRNA differential
display, serial analysis of gene expression (SAGE),
cDNA microarray, large-scale cDNA sequencing,
expressed sequence tag (EST) database comparison,
two-dimensional gel electrophoresis of cellular
proteins, subtractive library construction, repre-
sentational difference analysis (RDA) and sup-
pression subtractive hybridization (SSH).
5-8 The
mRNA differential display is complicated and
labor-intensive, and both SAGE and cDNA array
are limited for identifying unknown genes because
they formerly require known genetic informa-
tion.
2,9-11 The chip technology is highly efficient,
but also requires formerly known genetic informa-
tion and expensive equipment for making the
analysis. Thus, chip technology is not yet widely
available for the searching of unknown genes in
glioblastoma study.
12-14
Suppression subtractive hybridization (SSH) is
an efficient and versatile PCR-based method of
identifying rare, tumor-specific transcripts.
2,11,13
Since the development of glioblastoma is a com-
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plex process involving a large number of genes,
we believe that it is important to identify addi-
tional new genes, which might be involved in the
formation of this tumor. To this end, we employed
the SSH technique, which was originally
designed to identify genomic differences between
two complex genomes. SSH was later adapted to
isolation of gene transcripts which are differ-
entially expressed in one sample relative to
another, allowing the detection of low-abundance
transcripts in a sample. SSH is a powerful
technique that enables researchers to compare
two populations of mRNA and obtain clones of
genes that are expressed in one population but
not in the others.
15-20
In this report, over-expressed genes involved in
glioblastoma were identified by SSH, charac-
terized by RT-PCR and sequenced. The result
obtained from SSH screen was confirmed by RT-
PCR of non-neoplastic brain tissue, human glioma
cell lines and other human cancer cell line. To
know whether these genes are involved in the cell
division, serum deprivation and stimulation were
conducted.
MATERIALS AND METHODS
Tissue materials
Through June 2004 to September 2005, glio-
blastoma patients consented to use of their
tissues. We investigated tissues from 15 patients
in whom craniotomy and surgical removal were
performed due to cerebral glioblastoma. Tumor
and non-tumor brain tissues (tumor tissues; N =
15, non-tumor brain tissues; N = 15) were col-
lected during the neurosurgical operations. The
patients altogether consisted of 15 patients - 5
females and 10 males, aged 49 to 70 years. Mean
age at diagnosis was 55.2 years ± 6.9 (SD). The
histological diagnosis was made by two neuro-
pathologists according to World Health Organiza-
tion (WHO) classification of the astrocytic tumors.
Among 15 pairs of tissues (non-tumor brain tissue
and glioblastoma tissue), 10 pairs was used for
identification of new glioblastoma specific genes
and remaining 5 pairs for expression of identified
genes.
RNA extraction and SMART
TM PCR cDNA
synthesis
Total RNA of the non-tumor brain tissue and
glioblastoma tissue was prepared using the Trizol
reagent according to manufacturer’s instructions
(Clontech, Mountain View, CA, USA). The con-
centration and quality of each RNA sample were
measured for the synthesis of high quality cDNA
by spectrophotometrical determination of a 260/
280 ratio. About 1 g of total RNA samples was μ
treated with DNase I at 37°C for 15 min and at
65°C for 10 min, to get rid of genomic DNA con-
tamination. The RNA was dissolved in DEPC-
treated water and total RNA was analyzed on
1.2% agarose gel. Total 1 g RNA was used for μ
SMART cDNA synthesis and was reverse-trans-
cribed in 10 L mixture with PowerScript μ
TM Reverse
transcriptase (BD Biosciences Clontech, Mountain
View, CA, USA). The first-strand of cDNA was
diluted to a final volume of 40 L with 1 μ × TE
buffer (10 mM Tris-HCl, pH 8.0, 1 nM EDTA).
One L of the diluted cDNA was used to generate μ
cDNA by long distance PCR with BD Advantage
2 polymerase mix (BD Biosciences Clontech, CA,
USA), using PCR primer II A according to the
manufacturer’s instructions. The final concentra-
tion of digested second strand cDNA was 300 g/ μ
L. μ
PCR-based suppression subtraction hybridization
(SSH)
SSH was performed with the PCR-Select
cDNA Subtraction Kit according to the
manufacturer’s protocol. Driver ds cDNA was
synthesized from 1 g each of total RNA, using μ
SMART
TM PCR cDNA Synthesis Kit user Manual
(Clontech, Mountain View, CA, USA). First- and
second- strand cDNA synthesis and blunt-ending
of DNA ends by T4 DNA polymerase were
carried out according to the manufacturer’s
protocol. The second double-stranded cDNA was
digested with 10 units/ul RsaI in a final volume
of 50 L at 37°C for 3 μ hr. After extraction and
precipitation of digested second strand cDNAs,
the pellet was dissolved in 7 L of sterile H μ 2O,
precipitate was washed in 80% ethanol and
residual ethanol was evaporated after theIdentification of Up-regulated Genes in Malignant Glioma with Subtraction Hybridization
Yonsei Med J Vol. 49, No. 2, 2008
supernatant was removed. The final concen-
tration of driver was 300 ng/ L. RsaI digested μ
ds tester cDNA was prepared as described
above for the driver. Digested tester cDNA (1 L) μ
was diluted in 5 L of H μ 2O. The diluted tester
cDNA (2 L) was then ligated to 2 μ L of adaptor μ
land adaptor 2R (10 LM) in separate ligation μ
reactions in a total volume of 10 L at 16°C μ
overnight, using 400 units/ L of T4 DNA ligase μ
in the buffer supplied from the manufacturer.
After ligation, 1 L of 20(EDTA/glycogen was μ
added and the samples were heated at 72°C for
5min to inactivate the ligase and stored at -
20°C.
cDNA hybridization was used with tester1-1
and tester1-2 that were, mixed with adaptor1
and adaptor 2R respectively. One and half L of μ
tester1-1 with adaptor1 and tester1-2 with
adaptor 2R were, respectively, hybridized with
1.5 L digested first stranded driver cDNA of μ
brain tumor in 1 L of 4 μ × hybridization buffer
solution at 68°C for 8 hr. Tester1 - 2 hybridiza-
tion sample was drawn into the pipette tip.
Afterwards, 1 L of denatured mixture from 1 μ
L of digested second stranded driver cDNA, 2 μ
L of H μ 2O, and 1 L of 4 μ × hybridization buffer
solution at 98°C were drawn into pipette tip
with a slight air space below the droplet of the
above tester1-2 hybridization sample. The final
hybridization was then diluted in 200 L of μ
dilution buffer (20 mM HEPES/50 mM NaCl/0.2
mM EDTA), heated at 68°C for 7 min and
stored at - 20°C. For each subtraction, we per-
formed two PCR amplifications. The primary
PCR was conducted in 25 L. It contained 1 μ L μ
of diluted, subtracted cDNA, 1 L of PCR μ
primer 1 (10 M), and 23 μ L of PCR master μ
mixture prepared by using the 50 (Advantage
cDNA polymerase PCR Kit (Clontech, Mountain
View, CA, USA). PCR was performed with the
following parameters: 75°C for 5 min; 30 cycle
at 94°C for 25 sec, 94°C for 10 sec, 64°C for 30
sec, 72°C for 1.5 min. three L of primary PCR μ
mixture was diluted in 27 L of water for the μ
nested-PCR reaction for 11 cycle (94°C for 10
sec, 68°C for 30 sec, 72°C for 1.5 min) with the
same reagent except the two nested primer1,
2R.
Transformation and sequencing of the subtracted
cDNA
The subtracted cDNAs obtained after secondary
PCR were cloned with a T/A Cloning Kit
(Promega, Madison, WI, USA). The cDNAs were
ligated into T/A vectors by incubating 3 L of μ
the secondary PCR amplification and 1 L of the μ
vector (50ng/ L) with 3Weiss units of T4 DNA μ
ligase overnight at 4°C. Then, 5 L of ligated μ
product was transformed into 50 L of com μ -
petent JM109 cells for heat shock. Competent
JM109 cells transformed by ligated product were
grown on LB medium agar plates overnight at
37°C. White colonies containing inserts were
obtained, following transformation of competent
cells. White colonies were placed into LB
medium and shaken overnight at 37°C. The
plasmid DNA with inserted fragments was
extracted, the extracted DNA was digested with
EcoRI restriction enzyme, and the product was
analyzed on 1.2% agarose gel. DNA sequencing
was performed at Biotechnology Center
Macrogen (Seoul, Korea). Nucleic acid homology
was searched using the NCBI BLAST program
(http:/ /www.ncbi.nih.gov/BLAST).
RT-PCR
For expression of isolated seven genes' mRNA
levels on glioblastoma tumor tissues and non-
tumor brain tissue, RT-PCR was performed
using previous primers. mRNA of glioblastoma
tissue sample and non-tumor brain tissue which
were mentioned above samples was reverse
transcribed to cDNA using Superscript
TM First-
Strand Synthesis (Invitrogen, Carlsbad, CA, USA).
RT-PCR was performed on samples with 1 g of μ
total RNA. The reaction mixture contained 1 L μ
of SuperScript II reverse transcritase (50 units), 1
L μ oligo dT (0.5 g/ L μ μ ), 2 L μ 10X RT buffer, 2 L μ
of 0.1 M DTT, and 1 L μ each of 10 mM dNTP.
The reverse transcription was carried out for 50
min at 42°C. Semi-quantitative RT-PCR was used
to assess amounts of mRNA in glioblastoma
tissue sample and non-tumor brain tissue. PCR
amplification was performed with gene specific
primer, and 18srRNA was used as the reference
gene using the TaKaRa Ex Taq
TM. Gene specificYong Jae Cho
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primers used in this study were designed from
known sequences of the isolated genes, shown in
Table 1. Amplification conditions were denatura-
tion at 94°C for 5 min, followed by 35 cycles of
denaturation at 94°C for 30 sec, annealing at
55°C for 30 sec and extension at 72°C for 30 sec.
A final extension was done at 72°C for 10 min,
and the reaction mixtures were then run for 30
min at 100V on 1% agarose/EtBr gel with
ethidium bromide staining. Densitometric analyses
were performed including standardization from
the control (18srRNA) band.
RT-PCR analyses were performed to identify
genes in five human glioma cell lines (SF188,
SF539, SF126, U87, and U251) (Seoul National
University Cancer Research Center, Seoul, Korea).
The same methodology described above was used.
And also, RT-PCR was also done in other human
cancer cell lines; lung (WI-38), colon (CCD-18Co),
prostate (RWPE-1), SV40-immortalized cell line
(WI-38 VA13), lung carcinoma (NCI-H596), colon
carcinoma (KM1214) and prostate carcinoma
(DU145). These cell lines were purchased from
ATCC (Manassas, VA, USA) and Nikken Cell line
bank (Japan).
Serum deprivation and stimulation test
WI-38 (8PDL) cells were routinely maintained
in Eagle's minimal essential medium (E-MEM)
supplemented with 10% fetal bovine serum and,
essential and non-essential amino acids. Cells
were seeded at a density of 2× 10
6 cells in a 60-mm
dish. The cultures were maintained at 37°C in a
humidified 5% CO2 atmosphere. They were
cultured at a density of 60% cells, washed with
PBS, and medium supplemented with 1% FBS was
finally added. The cells were washed with PBS
after 48 h and supplemented with 10% fresh FBS
medium. Cells were then harvested at 0, 0.5, 1, 2,
4, 6, and 16 hr after the 10% FBS treatment. To
identify the expression, "clones 7, 10, 15, 25, 28, 43,
and 47" mRNA levels were analyzed by RT-PCR.
PCR was performed using the TaKaRa Ex Taq
TM
under the following conditions: first 3 min at
94°C, then 30 sec at 94°C, 30 sec at 55°C, 30 sec
at 72°C for 35cycle, and 10 min at 72°C. After
PCR, each of the PCR products was electrophore-
tically resolved on 1.2% agarose gel and stained
with ethidium bromide.
Table 1. The Primer Sequences of Genes of Interest
Clones Primer sequences Size (bp)
Clone 7 Sense: 5’-ATACCTCACATGCTCTCCAC-3’ 
Anti-sense: 5’-ATTTTGTAAAGGGCTTCCTC-3’ 
161
Clone 10 Sense: 5’-AGTTCAATTTTGTGGGATTG-3’
Anti-sense: 5’-AAGGGGATTTCTTAAGGTTG-3’
153
Clone 15 Sense: 5’-CCATTTTATTTCTGACCCCT-3’ 
Anti-sense: 5’-AGTCATTCCTGACCTGAGTG-3’ 
206
Clone 25 Sense: 5’-ACAGAGCCAGTTGTGTTTTT-3’
Anti-sense: 5’-GGTTCTACGGTGAATCTCAA-3’
217
Clone 28 Sense: 5’-CCTAGGAGACATCAAACAGC-3’ 
Anti-sense: 5’-GGGAGTGCCTTATAATGATG-3’  
208
Clone 43 Sense: 5’-GGTTCCTCCTACAGGGTATT-3’
Anti-sense: 5’-GTCTTACAGGTCAGCGATTC-3’
288
Clone 47 Sense: 5’-CCACAGGTATCTCCCACTAA-3’ 
Anti-sense: 5’-CTACCTTCCCTTCCTCATCT-3’  
222
18srRNA Sense: 5’-TACCTACCTGGTTGATCCTG-3’
Anti-sense: 5’-GGGTTGGTTTTGATCTGATA-3’
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RESULTS
Identification of new over-expressed genes in
glioblastoma using SSH
With this experimental design, 130 plasmid
clones were obtained. The digested cDNA clones
were searched for sequence homologies in the
GenBank DNA database by BLAST. DNA
sequencing results of the digested 130 clones were
found to have high homology to 14 genes known
in the public database of the 14 kinds (Table 2).
We identified 21 unknown genes, which were not
homologous to any of the known genes in the
Genbank database (Table 3). Among these 21
genes, we selected 7 genes which were over- ex-
pressed in glioblastoma, compared to non-tumor
brain tissue (Fig. 1). To be considered over-ex-
Fig. 1. RT-PCR analysis for differential expression of 21 clones between glioblastoma and non-tumor brain
tissue. We selected seven genes for RT-PCR. N, non-tumor brain tissue; T, glioblastoma.
Table 2. Identification of Known Genes from SSH Libraries
GeneBank accession number Matching gene
AY034480
U28386
BC000260
AF267864
AF346971
NM_000980
BC056870
U94747
X64644
AF276948
AY335768
AF328729
X98294
AY327035
S100 calcium-binding protein A6 gene
hSRP1 alpha (Karyopherin alpha 2)
Aldo-keto reductase family 1
DC42 mRNA
Mitochondrion
Ribosomal protein L18a (RPL18A), mRNA
Voltage dependent anion channel 3
WD repeat protein HAN11 mRNA
C6.1B mRNA
HMG box containing protein (HBP2)
Tumor rejection antigen 1gp96 (TRA1)
CTCL tumor antigen
DNA double-strand break repair
Ixodes ricinus cytochrome oxidase subunit 1mRNAYong Jae Cho
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pressed in glioblastomas, the genes tested had to
show a threefold greater expression in tumor
samples than in non-tumor brain tissue by semi-
quantitative RT-PCR. In this study, we considered
these genes as candidates for over-expressed
genes in glioblastoma.
Different expression of genes in glioblastoma
tissues and non-tumor brain tissue
To examine whether these new genes were ex-
pressed specifically in glioblastoma tissues, the
expression patterns of transcription were ex-
amined by RT-PCR analysis for remaining 5
resected pairs of glioblastoma tissues and
non-tumor brain tissues. The expressions of clone
25 were found to be relatively over-expressed as
compared with non-tumor tissues (Fig. 2). The
remaining six clones were not clear.
Expression of genes in human glioma cell lines
and other human cancer cell lines
In comparison of five commercial glioma cell
lines, the expression profiles of various cell lines
could be categorized into two groups (Fig. 3): (1)
genes that were over-expressed by all cell lines
(clone 7, 25, 28), (2) genes that showed weak
expression across the cell lines without any
distinct pattern (clone 10, 15, 43, 47).
Table 3. Unknown 21 Clones by BLAST Program
Clone Matching gene
10, 69 Homo sapiens chromosome 16 clone
13 Homo sapiens
14, 40 Homo sapiens genomic DNA, chromosome 11
15, 16, 42 Human DNA sequence from clone RP11-20F24
20 Homo sapiens cDNA clone IMAGE:3842446
25 Homo sapiens clone RP11-340F1 from 7p14-15
28 Homo sapiens chromosome 16 clone RP11-132F7
32 Human DNA sequence from clone RP11-454L1
34 Homo sapiens chromosome 17, clone RP11-580I16
37 Sinorhizobium meliloti 1021 complete chromosome
41 Homo sapiens chromosome 5 clone RP11-265K23
43 Homo sapiens 12 BAC RP11-15I13
47 Human chromosome 14 DNA
50 Homo sapiens, clone MGC:13410
54 Homo sapiens, clone IMAGE:3951562
57 Human DNA sequence from clone RP11
58 Human DNA sequence from clone RP11
60 Homo sapiens, clone MGC:22874
9, 65, 67 Homo sapiens, clone MGC:13410
68 Homo sapiens chromosome 15
7 Homo sapiens BAC clone RP11Fig. 3. Expressions of seven genes'
mRNA from glioma line by RT-PCR.
The expressions of mRNA of seven
clones were significantly higher than
those in non-tumor brain tissues. In
glioma cell lines, two different types of
gene expression profile were observed.
One type was genes that were over-
expressed by all the cell lines (clone 7,
25, and 28), whereas the other was
genes that showed variable expression
across the cell lines without any
distinct pattern (clone 10, 15, 43, and
47). 18srRNA (control) demonstrates
equal expression across the panel. NBT,
non-tumor brain tissue.
Fig. 2. Expression of seven genes’ mRNA levels
from glioblastoma tissues by RT-PCR. The
expressions of clone 7 were higher than those in
non-tumor brain tissues. N, non-tumor brain
tissues; T, glioblastoma tissues; 18srRNA, control.
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The expressions of clones 7 and 28 were not
specific to other cancer cell lines, except it was
weakly expressed in lung cancer cell line. As
shown in Fig. 4, the mRNA expressions of clones
10, 15, 25, 43, and 47 were determined to be
over- expressed in human lung cancer, prostate
cancer cells compared with human non-cancer
cell lines.
Serum deprivation and stimulation
As shown in Fig. 5, the time course experiment
showed that WI-38 cells starved in serum-free
medium did not show mRNA expression at 0 hr.
After 10% FBS treatment, however, each clone
was found to express the mRNA.
DISCUSSION
Identification of genes that are differentially
expressed between brain tumor tissue and normal
brain tissue is very important for understanding
the molecular basis of these nervous tumors and
for defining possible targets for therapeutic
intervention.
3,21 Human glioblastoma, as with many
human cancers, is characterized by genetic and
phenotypic heterogeneity despite a fairly uniform
appearance by light microscopic findings.
1,22 Our
study was designed to identify genes with differ-Yong Jae Cho
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ential expression between glioblastomas cells and
non-neoplastic brain cells.
To achieve our goal, we have used the SSH
that is suited ideally for the identification of
over- expressed genes. When we used the tester
(glioblastoma tissue) and driver (non-tumor brain
tissue) DNA fragments, the drives cDNA would
eliminate the sequences common between the
tester and driver cDNA samples during the first
and second hybridization step. To determine the
efficiency of the SSH, both the subtracted and
unsubtracted cDNAs have to be amplified by
PCR with GAPDH primers for different cycles:
18, 23, 28, and 33 cycle. The expression of
GAPDH was observed in unsubtracted cDNA
after 18 cycles and after 33 cycles in subtracted
cDNA. In this result, the abundance of GAPDH
decreased significantly after subtraction. It was
important to confirm that individual clones
indeed represent differentially expressed genes.
In the present study, we isolated known genes as
well as new genes that were over-expressed in
glioblastoma tissue as compared to non-tumor
brain tissue.
Over 130 libraries were screened after SSH,
from which 21 differentially regulated clones were
identified. The percentage of up-regulated clones
was, therefore, approximately 16%. Of the 21 clones
identified, 6 clones were multiple hits, and we
selected 7 genes for further evaluation. (Table 3)
In most glioblastoma samples, the expression of
mRNA of clone 25 was distinctly higher than that
in non-tumor brain tissues (Fig. 2). On the whole,
the expressions of six clones except clone 47 were
relatively higher than non-tumor tissue. The
uniform expression of control 18srRNA indicates
equal template loading of the RNA from the
tumor specimen.
The expression profiles of the 7 genes in five
human glioma cell lines were categorized into two
groups. In contrast to expressions of clones 10, 15,
43, and 47, those of clones 7, 25, and 28 were over-
expressed by all the glioma cell lines. Especially,
the clone 7 and 25 clearly showed over-expres-
sions.
In various human cancer cell lines, the expres-
sions of the clones 7, 25 and 28 were either weak
or not detectable, however, those of clones 10, 15,
25, 28, 43, and 47 were relatively over-expressed
Fig. 4. Expressions of seven genes’ mRNA from various
human cancer cell line by RT-PCR. Lane 1, normal lung
(WI-38); Lane 2, SV40-immortalzed (WI-38 VA13); Lane 3,
Lung carcinoma (NCI-H596); Lane 4, Normal colon
(CCD-18CO); Lane 5, Colon carcinoma (KM 1214); Lane 6,
Normal prostate (RWPE-1); Lane 7, Prostate carcinoma
cell line (DU 145); and control (18srRNA).
Fig. 5. Serum deprivation and stimulation. The expres-
sions of seven genes were significantly increased 0.5 and
1 hr after 10% FBS treatment. After 2 hr of treatment,
the levels of seven genes' mRNA a drastically decreased.Identification of Up-regulated Genes in Malignant Glioma with Subtraction Hybridization
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in other cancer cell lines. Four out of 7 genes were
up-regulated by immortalization in lung fibroblasts.
Those expressions in immortalized fibroblasts
might suggest that the expressions of RT-PCR
were due to proliferating state of dividing cells,
but not due to quiescent cells. On the other hand,
the rest of the genes were not up-regulated in
immortalized fibroblasts. The weak expressions of
the clones 7 and 28 were observed compared to
normal lung line, but expression of these genes in
glioma cell line was strong. It is highly likely that
some genes of specific cancer would be involved
also in other cancer, because of multiplicity of
oncogene. In cancer cells, their expression is due
to particular genes and shared with other genes
in different degrees by in other cancers.
Clones 7 and 28, which were not or weakly
expressed in the other cancer cell lines, were
expressed in the glioma cell line suggesting that
these genes may be related to glioblastoma.
Clones 10, 15, 28, 43, and 47 were expressed
non-specifically in human glioma cell line and
expressed variously in other human cancer cell
lines, so these clones can represent genes that are
related in a proliferate state regardless of tumor
phenotype. In serum deprivation and stimulation,
it is said that theses seven genes are related to
cell division. But, the expressions of 5 out of 7
genes (clone 10, 15, 25, 43, 47) were increased by
serum deprivation and stimulation, indicating
some uncertainty of our experiments: It might
have been influenced by culture medium
condition. Clone 7 needs to be further functional
studied.
Our present study is preliminary to derive any
definite conclusion. We have cloned one or two
over-expressed genes. Its significance and roles
are unclear. Further studies are needed to charac-
terize functional significance and roles of these
genes in glioblastoma tumorigenesis and pro-
gression.
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